<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38352">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718522</url>
  </required_header>
  <id_info>
    <org_study_id>CEN_G_DB_1</org_study_id>
    <nct_id>NCT01718522</nct_id>
  </id_info>
  <brief_title>RANSuP Registerstudie</brief_title>
  <acronym>RANSuP</acronym>
  <official_title>Registerstudie: Anwendung Und Nutzen Der Sensorunterstützten Pumpentherapie (SuP) Unter Alltagsbedingungen (RANSuP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to collect the real life data on Sensor Augmented pump
      therapy usage in type 1 DM patients treated with Medtronic Insulin pumps and countinuous
      glucose monitoring systems in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>to assess the glycemic control in the study population:</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>primary outcome based on:
Frequency of hypoglycaemia´s under SaP (AUC in hypoglycaemic region &lt;70mg/dl and time spent in hypoglycaemic region)
Frequency of hypoglycaemia´s (glucose values &lt; 40 mg/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameters of glycaemic control</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>HbA1c, mean glucose concentration, standard deveation of glucose concentration, AUC in hyperglycaemic region (&gt;160mg/dl), glucose excursions after meals (amplitude of excursions), time spent in hyperglycaemic region (&gt;160mg/dl), day time of appearance of dysglycaemic events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>Focus of the Study is to Collect Data and to Get Experience in the Application of Glucose Sensors in the Therapy With Insulin Pumps Under Daily Life Conditions</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 diabetes mellitus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with signed informed consent

          -  Type 1 DM and has been on insulin pump therapy for at least 3 months prior to
             signature of the informed consent

          -  patients use CGM component as part as part of the CSII therapy for a minimum of 1
             month

        Exclusion Criteria:

          -  participation in any other trial

          -  any disease or drug treatment that can interfere with the outcome of sensor usage

          -  using CGM in CSII &lt; 3 days/week

          -  patients not willing to sign informed consent

          -  abuse of alcohol or drugs (exception of nicotine consumption)

          -  eating disorder, anorexia, bulimia or other mental disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
